Your browser doesn't support javascript.
loading
Sarcopenia as a Predictor of Feeding Tube Placement in Individuals with Oropharyngeal Cancer.
Jovanovic, Nedeljko; Palma, David A; Warner, Andrew; Mitchell, Sylvia; Doyle, Philip C; Theurer, Julie A.
Afiliación
  • Jovanovic N; Health and Rehabilitation Sciences, Western University, London, Canada.
  • Palma DA; Department of Radiation Oncology, London Health Science Centre, London, Canada.
  • Warner A; Department of Radiation Oncology, London Health Science Centre, London, Canada.
  • Mitchell S; Department of Radiation Oncology, London Health Science Centre, London, Canada.
  • Doyle PC; Department of Otolaryngology - Head and Neck Surgery, Division of Laryngology, Stanford University School of Medicine, Stanford, California.
  • Theurer JA; Health and Rehabilitation Sciences, Western University, London, Canada.
Adv Radiat Oncol ; 9(6): 101484, 2024 Jun.
Article en En | MEDLINE | ID: mdl-38681896
ABSTRACT

Purpose:

In oropharyngeal squamous cell carcinoma (OPSCC), systemic loss of skeletal muscle mass (SMM), or sarcopenia, is a strong prognostic predictor of survival outcomes. However, the relationship between sarcopenia and nutrition-related outcomes is not well understood. This investigation evaluated the prognostic significance of sarcopenia for feeding tube (FT) placement in a cohort of OPSCC patients. Methods and Materials A retrospective cohort study was conducted with data collected from 194 OPSCC patients treated with definitive radiation therapy (RT) or chemoradiation therapy (CRT). Sarcopenia was assessed from computed tomography imaging at the level of the third cervical (C3) and fourth thoracic (T4) vertebrae. The prognostic nature of pretreatment sarcopenia and its relationship with FT placement was explored using logistic regression.

Results:

The median age of patients included was 61.0 years, and the majority were male (83%). In this patient cohort, 87.6% underwent concurrent CRT, and 30.9% received a FT over the course of treatment. Sarcopenia was identified at baseline in 72.7% of patients based on C3 SMM measurements and in 41.7% based on measures at the level of T4. Based on measures at both C3 and T4, those with sarcopenia were significantly more likely to receive a FT and had significantly worse freedom from FT placement compared with patients without sarcopenia. Sarcopenia assessed at T4 was a significant predictor of FT placement.

Conclusions:

SMM measured at T4 may represent a novel and practical biomarker for sarcopenia detection that is associated with the need for FT placement. These findings suggest that the detection of baseline sarcopenia could guide decision-making related to the need for nutritional support in OPSCC patients undergoing RT/CRT.

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Adv Radiat Oncol Año: 2024 Tipo del documento: Article País de afiliación: Canadá

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Adv Radiat Oncol Año: 2024 Tipo del documento: Article País de afiliación: Canadá